U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer ’s Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age and Older
NEW YORK--(BUSINESS WIRE)-- December 08, 2020 Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review a Biologics License Application (BLA) for its 20-valent pneumococcal conjugate vaccine...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Clinical Trials | Food and Drug Administration (FDA) | Meningitis Vaccine | Pfizer | Pharmaceuticals | Pneomococcal Vaccine | Vaccines